Citramel trial completes successful Phase I

Citramel trial completes successful Phase I and kicks into
second gear for Phase IIa

A patient takes part in the first phase of Breathe Easy’s Citramel cystic fibrosis drug at the Christchurch Clinical Studies Trust.

Citramel, a locally developed therapy with potential to improve the lives of thousands worldwide living with cystic fibrosis has been given the green light to move into the next phase of clinical trials in New Zealand, following completion of the first stage of trials.

Phase I trials of Citramel on healthy subjects in Christchurch indicated that the treatment was well tolerated and safe. The company behind the therapy, Breathe Easy has just announced a wider Phase IIa trial which will take place in Christchurch and Auckland, with leading respiratory physicians from both regions overseeing it.

It is the first early stage trial for a cystic fibrosis therapy in New Zealand, and is unique in that the therapy itself was developed here.

Chairman of Breathe Easy’s Scientific Advisory Board, Dr Paul Tan, says running dual sites presents significant advantages for the trial timeline.

“Conducting trials in Auckland and Christchurch simultaneously enables us to complete this second phase faster. We are now recruiting subjects in varying stages of severity of this disease and from different treatment backgrounds, from around the country.”

Breathe Easy CEO, Andrea Miller, says it’s been a long road to get to this stage, but it’s coming together now more rapidly.

“This time last year we were head down in fundraising mode, with trials just a distant vision. Now, 12 months later we’re heading into Phase IIa, with those results likely to be out later next year. If this is as successful as we hope, then we should have multiple options to fund bigger trials and include another country.”

Families around New Zealand interested in taking part in these trials can find more information by contacting us

Comments are closed.